Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd Sells 1,500 Shares of Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $121.53 on Thursday. The firm has a market cap of $7.35 billion, a price-to-earnings ratio of 17.12, a PEG ratio of 0.90 and a beta of 0.56. The company has a 50 day moving average of $122.60 and a 200-day moving average of $116.32. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Franklin Resources Inc. grew its holdings in Jazz Pharmaceuticals by 4.6% during the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after acquiring an additional 48,708 shares during the period. Thompson Siegel & Walmsley LLC grew its holdings in Jazz Pharmaceuticals by 8.3% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock worth $87,035,000 after acquiring an additional 59,685 shares during the period. Perpetual Ltd grew its holdings in Jazz Pharmaceuticals by 10.4% during the 3rd quarter. Perpetual Ltd now owns 675,431 shares of the specialty pharmaceutical company’s stock worth $75,250,000 after acquiring an additional 63,564 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock worth $59,238,000 after acquiring an additional 42,587 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several research analyst reports. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Piper Sandler reiterated an “overweight” rating and issued a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.